ArticleJournal of spine surgery (Hong Kong)2026
Stereotactic radiosurgery for NF2-related schwannomatosis and schwannomatosis-associated spinal tumors: a single-institution cohort.
Article in Journal of spine surgery (Hong Kong), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurofibromatosis type 2 (NF2)-related schwannomatosis and other schwannomatosis subtypes frequently involve multiple spinal nerve-sheath tumors. While stereotactic radiosurgery (SRS) is well established for intracranial disease, long-term spinal outcomes in genetically predisposed populations remain limited. Existing spinal SRS studies often include heterogeneous tumor types, limited follow-up and/or mixed sporadic and syndromic cohorts. This study reports a 21-year single-institution experience, including rare long-term follow-up extending to 19 years. Methods: We retrospectively reviewed 13 patients with NF2-related schwannomatosis, schwannomatosis-not otherwise specified (schwannomatosis-NOS), or misclassified NF1 who underwent CyberKnife SRS for 23 spinal tumors between 2004-2025. Demographics, tumor characteristics, GTV/PTV definitions, dose constraints, and CTCAE-graded toxicities were recorded. Radiographic control and functional outcomes were assessed. Results: Median age was 39 years (interquartile range, 24-49 years); 69.2% were male. Tumors included 15 schwannomas (65.2%), 7 neurofibromas (30.4%), and 1 meningioma (4.3%). Mean prescription dose was 18.5±2.7 Gy (median 1 fraction). CTCAE-graded toxicities included Grade 1-2 sensory symptoms (15.3%) and Grade 1-2 motor symptoms (15.3%); no Grade ≥3 events occurred. At follow-up, 17.4% regressed and 34.8% remained stable. Functional improvement occurred in 22.2% of evaluable lesions. One radiographic recurrence (4.3%) was identified. Illustrative cases demonstrated feasible and durable long-term control, including an 8-year stable cervical neurofibroma treated at age 18 years, a thoracolumbar schwannoma case with 9-year stability across multiple treated levels, and a lumbar schwannoma achieving local control without acute toxicity following hypofractionated SRS. Conclusions: SRS may be considered a safe, targeted option for selected spinal tumors in NF2-related schwannomatosis, particularly in cervical lesions. Prospective studies incorporating molecular stratification and adaptive radiotherapy are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.